Tki 023

By
admin
-
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management | Signal Transduction and Targeted Therapy

Meet Tki Francis - CanvasRebel Magazine

CanvasRebel Magazine

Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology

AHA Journals

NOTCH4ΔL12_16 sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1 | Nature Communications

Nature

An epigenetic switch regulates the ontogeny of AXL-positiveEGFR-TKi-resistant cells by modulating miR-335 expression | eLife

eLife

How should we interpret conclusions of TKI-stopping studies | Leukemia

Nature

Frontiers | Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance

Frontiers

Frontiers | Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments

Frontiers

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy | Molecular Pharmaceutics

ACS Publications - American Chemical Society

Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema | Eye

Nature

Researchers pinpoint protein tied to drug resistance in patients with lung cancer

Medical Xpress

Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer | Nature Reviews Clinical Oncology

Nature

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast | Targeted Oncology

SpringerLink

Frontiers | Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis

Frontiers

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology

healthbook TIMES Oncology Hematology

PDF) Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

ResearchGate

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity | Science Immunology

Science

A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells | Request PDF

ResearchGate

Association of white matter hyperintensities with long‐term EGFR‐TKI treatment and prediction of progression risk - Yang - Brain and Behavior - Wiley Online Library

Wiley Online Library

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)

Spandidos Publications

Related Posts

Pornme
/pornme

Pornme

SMG-Admin -
3
ราคา หก ล้อ ฮี โน่
ฮีโน่

ฮีโน่ ราคา หก ล้อ ฮี โน่

SMG-Admin -
1